Skip to main content

Table 2 Viability of pancreas cancer cell lines following treatment with sigma-2 ligands and gemcitabine.

From: The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Gemcitabine - + - + - + - +
Cell Line DMSO SV119 SW43 SRM
Panc02 100 50 ± 3 79 ± 7 39 ± 1 24 ± 5 14 ± 2 6 ± 0 2 ± 2
Panc1 100 47 ± 5 81 ± 6 41 ± 5 43 ± 5 19 ± 4 8 ± 4 3 ± 3
BxPC3 100 71 ± 1 66 ± 2 52 ± 1 43 ± 4 33 ± 4 8 ± 2 2 ± 1
Cfpac 100 40 ± 8 88 ± 4 40 ± 4 60 ± 6 21 ± 7 8 ± 5 4 ± 2
  1. Pancreas cancer cell lines were pretreated with gemcitabine (0.5 uM) or vehicle for 24 hours followed by sigma-2 ligand (25 uM) treatment for 18 hours and viability represented as percentage relative to vehicle, (mean ± SEM), n ≥ 3.